Since the beginning of the year, corporate crypto treasury strategies have been multiplying around the world. This momentum seems determined to integrate the sector’s leading cryptocurrencies, as in the case of the very first Litecoin (LTC) fund launched by MEI Pharma.
MEI Pharma launches the first Litecoin (LTC) corporate treasury
Following their unprecedented inclusion in the development strategies of publicly traded companies, the question is no longer whether, but when the top 50 cryptocurrencies will have their own dedicated corporate treasuries.
A new-generation economic model is moving from the status of a visionary project, largely promoted by Strategy, to a kind of strategic imperative. The goal is to avoid missing out on the institutional and stock market adoption that this implies.
Clearly, Litecoin founder Charlie Lee has learned his lesson well. He has just participated as a strategic advisor—and new board member—in the launch of the first corporate treasury dedicated to the LTC cryptocurrency, set up by MEI Pharma.
Litecoin has long been a healthy, scalable, and decentralized currency. By launching this strategy, MEI Pharma is taking a decisive institutional step forward in recognizing Litecoin’s role as both a reserve asset and an essential component of global financial systems.
Charlie Lee
A fund estimated at over $100 million
To initiate this crypto treasury project, MEI Pharma purchased a total of 929,548 LTC at an average price of $107.58. As a result, its dedicated Litecoin fund is currently estimated at $110 million at the price of LTC. No notable upturn has been observed in MEIP’s share price over the last few days, but it seems important to note a significant rebound of more than 90% since mid-July.
However, one question remains unanswered for the most knowledgeable crypto observers. Why choose Litecoin? The answer provided in MEI Pharma’s press release is divided into three distinct points:
- Flawless reliability, with uninterrupted availability for over 13 years;
- Proven operational efficiency, with minimal fees and fast transaction processing;
- Widespread adoption on platforms such as BitPay, Robinhood, PayPal, and Venmo, with a large network of users and merchants.
This momentum, backed by crypto investment firm GSR, “marks the beginning of a broader institutional treasury initiative for MEI Pharma.” Indeed, the company has announced its intention to “update its identity in the coming weeks” in light of this major development, but also to include the possibility of Litecoin-related mining activity in the near future. This move obviously does not call into question its core pharmaceutical business.
